PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GHENT, Belgium, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Aviva plc and Aviva Investors Global Services Limited.

The above shareholders notified that they have exceeded the 3% threshold and now hold 1,482,342 Ablynx shares, which represent 3.04% of the current 48,827,646 outstanding shares of Ablynx.

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings: Aviva plc (Parent Company), Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc), Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited), Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited).

Full versions of all transparency notifications are available on the website of Ablynx, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

press release in pdf format: http://hugin.info/137912/R/1739362/583729.pdf

CONTACT: Ablynx: Dr Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com Marieke Vermeersch Associate Director Investor Relations t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: marieke.vermeersch@ablynx.com Follow us on Twitter @AblynxABLX Ablynx media relations Consilium Strategic Communications: Mary-Jane Elliott, Amber Bielecka, Lindsey Neville t: +44 207 920 2345 e: ablynx@consilium-comms.comSource:Ablynx